BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

May 12, 2016
Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeutics for infectious diseases, talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the company's history, a development timeline for its leading drug candidate, Iclaprim, and why Motif recently decided to jump from being a drug discovery company to a clinical-stage biotech. Motif's lead product, which has just entered Phase III trials, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae).
Previous Video
BIO-Europe Spring® 2016: Where can Adocia fit in the diabetes market?
BIO-Europe Spring® 2016: Where can Adocia fit in the diabetes market?

Dr. Remi Soula, co-founder and director of business development and intellectual property at Adocia, chats ...

Next Video
BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars
BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars

Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to M...